Kroger Specialty Pharmacy is proud to announce it is now dispensing ALECENSA®, GAVRETO®, and ROZLYTREK® to expand our extensive list of specialty medications in Oncology.
Read MoreKroger Specialty Pharmacy is proud to announce it is now dispensing CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) for treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL), on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.
Read MoreThe ACO & Payer Leadership Summit is the premium forum bringing senior level executives from both public and private health plans, MCOs, ACOs, and integrated health systems together with solution providers.
Read MoreKroger Specialty Infusion is proud to announce it is now dispensing Xembify®, a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
Read MoreKroger Specialty Infusion is proud to announce it is now dispensing Cuvtiru, a subcutaneous treatment for patients with primary immunodeficiency (PI) in people 2 years and older.
Read MoreKroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization for the COVID-19 Test Home Collection Kit.
Read MoreThe Kroger Co. (NYSE: KR) today announced an agreement for Axium Pharmacy Holdings, Inc. (“Axium”) to acquire the outstanding shares of Modern HC Holdings, Inc. (“ModernHEALTH”), a leading specialty pharmacy, to create a combined specialty pharmacy.
Read More